Jones Lang LaSalle Inc vs Vaxcyte Inc. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.73B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| JLL | PCVX | |
|---|---|---|
Market Cap | $13.73B | $10.51B |
Volume | 368,437 | 2,644,694 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $73.82 |
52-Week Low | $280.16 | $40.32 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.49B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $295.25, down 0.96% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $20.9B in 2022 to $26.1B in 2025, and improving net margins. Recent acquisitions and strategic appointments highlight operational momentum, while analyst consensus remains bullish with a $450.50 price target.
The outlook is positive given valuation discounts (P/E 14.31, P/S 0.52) and robust cash flow growth, though risks include real estate market cyclicality and technical resistance near $297. Upside hinges on continued execution and sector tailwinds, supporting a constructive view for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →